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Abstract:  13 
Pulmonary delivery has high bioavailability, a large surface area for absorption and limited 14 
drug degradation. Particle engineering is important to develop inhalable formulations to improve 15 
the therapeutic effect. In our work, the poorly water-soluble meloxicam (MX) was used as an 16 
active ingredient, which could be useful for the treatment of non-small cell lung cancer, cystic 17 
fibrosis and chronic obstructive pulmonary disease. We aimed to produce inhalable 18 
“nano-in-micro” dry powder inhalers (DPI) containing MX and additives (poly-vinyl-alcohol, 19 
leucine). We targeted the respiratory zone with the microcomposites and reached a higher drug 20 
concentration with the nanonized active ingredient. We did the following investigations: particle 21 
size analysis, morphology, density, interparticular interactions, crystallinity, in vitro dissolution, in 22 
vitro permeability, in vitro aerodynamics (Andersen Cascade Impactor), in silico aerodynamics 23 
(stochastic lung model). We worked out a preparation method, by combining wet milling and 24 
spray-drying. We produced spherical, 3-4 µm-sized particles built up by MX nanoparticles. The 25 
increased surface area and amorphization improved the dissolution and diffusion of the MX. The 26 
formulations showed appropriate aerodynamical properties: 1.5-2.4 µm MMAD, 72-76% FPF 27 
values. The in silico measurements proved the deposition in the deeper airways. The samples were 28 
suitable for the treatment of local lung diseases. 29 
Keywords: dry powder inhaler, nano, meloxicam, wet milling, spray-drying, Andersen Cascade 30 
Impactor, in silico assessment 31 
 32 
1. Introduction 33 
The main advantages of pulmonary delivery are the result of the huge surface area of the lung 34 
(100 m2) with a thin absorption layer (0.1-0.2 µm), and low metabolic activity. Targeted delivery of 35 
the drug could provide benefits such as achieving a greater local concentration at the target site 36 
with a reduced dose, resulting in reduced systemic side effects and adverse events [1]. Local 37 
delivery is especially effective in patients with serious pulmonary diseases such as asthma, cystic 38 
fibrosis (CF), chronic obstructive pulmonary (COPD) disease and lung cancer [2].   39 
For the application of inhaled medications, dry powder inhalers (DPI) are more widely used, 40 
compared to nebulizers or metered-dosed inhalers (MDI). DPI products are solid-state, therefore 41 
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they have long term stability. The delivery is driven by the inhalation flow, thus DPI-s are 42 
environmentally friendly, they do not require a compressor or propellant. The administration time 43 
is very short, the devices are cheap and portable [3]. Unfortunately, drug deposition in the 44 
pulmonary region is not sufficient with the traditional carrier-based DPI inhalers. In these systems, 45 
the active ingredient is attached to the surface of a carrier, which is usually lactose, but it could be 46 
mannitol or glucose too. The potentiality of the powders is proper dispersion in the respiratory 47 
system, so the aerosolization of the products should be optimized. Hence new carrier-free DPI 48 
systems have been developed to enhance the therapeutic effect. To reach efficient deposition, DPI 49 
should contain a powder made of the active pharmaceutical ingredient (API) co-formulated with 50 
appropriate excipients, which are chosen based on their functions in the powder, leading to optimal 51 
aerodynamic properties [4]. Excipients approved for DPI formulations are for example hydrophobic 52 
additives (Mg-stearate) for protection against moisture, lipids (cholesterol) for coating, amino acids 53 
(leucine) for improved aerosol efficiency, absorption enhancers (cyclodextrins, chitosan) and 54 
biodegradable polymers (PLGA) for stability and released formulations [2]. 55 
Besides the components, the particle size and dispersibility of DPI-s have a key role in the 56 
deposition pattern. There are three principal mechanisms of particle deposition in the lung. Inertial 57 
impaction affects particles that are larger than 5 µm. These particles are not able to follow the 58 
changes of gas flow direction in the upper airway and at the airway bifurcations. Therefore, the 59 
particles impact on upper airways walls, limiting the amount of API that can be delivered into the 60 
lung. Gravitational sedimentation is based on the settling of particles under the action of gravity 61 
and occurs in the smaller airways and where the distance is covered by the particles before they hit 62 
the wall of the airways. This deposition mechanism is the most effective for particles in the size of 63 
1–8 µm. DPIs in this size range are best suited to treat central and small airways. Random motions 64 
of the particles caused by their collisions with gas molecules result in deposition by Brownian 65 
diffusion. Unlike deposition by impaction and sedimentation, which increase with increasing 66 
particle size, deposition by Brownian diffusion rises with decreasing particle size and becomes the 67 
dominant mechanism of deposition for particles less than 1 µm in diameter. These particles are 68 
effective in the alveolar region of the lung, where air velocities are low [5]. Particles under usually 1 69 
µm get exhaled. In conclusion, the requested particle size range in pulmonary therapy is a particle 70 
diameter of 1-5 µm. 71 
Nanoparticles are a beneficial formulation for Class II drugs of the Biopharmaceutics 72 
Classification System (BCS), where the dissolution rate is the rate-limiting step for absorption. The 73 
reduction of particle size can increase the dissolution rate since the amount of API dissolving over 74 
time is inversely correlated with the particle diameter. For this reason, nanoparticle formulations of 75 
API are being assessed for their potential to increase the drug dissolution rate as a result of higher 76 
specific surface area. If we formulate the nanosized API into micrometric particles, we can target 77 
the proper parts of the airways and when the powders contact with the lung lining fluid, the 78 
particles can disintegrate into their nano subunits and spread on the surface of the epithelium, 79 
resulting in a large surface area for drug dissolution, and therefore increased absorption and more 80 
homogenous distribution [6]. A prosperous formulation for nanoparticle agglomerates is the 81 
preparation of nanosuspensions by wet milling followed by solidification, using spray-drying. They 82 
are reproducible, scalable, cost and time-effective preparation methods. We can combine the 83 
advantages of nanonized particles by preparing a nanosuspension (i.e. enhanced dissolution and 84 
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solubility) with the benefits of solid formulations (i.e. stability, easier handling, enhanced patient 85 
compliance) by producing microsized nanoparticle agglomerates suitable for pulmonary delivery 86 
[7]. 87 
Our research group had experiences with meloxicam (MX) as an API and different additives, 88 
such as polymers and amino acids. In this work, we used MX, which is a poorly water-soluble (in 89 
water, 7.15 mg/L at 25 °C), non-steroidal anti-inflammatory agent [8]. In pulmonary therapy it 90 
could be useful to treat CF, COPD and non-small-cell lung cancer [9], [10], [11], [12]. Previous 91 
studies were about particle size reduction of meloxicam with wet milling using poly-vinyl-alcohol 92 
(PVA) solution as a dispersant [13]. In the presence of PVA, the particle size of the drug could be 93 
reduced to the nanometre range. In the case of co-spray-dried DPI formulations, PVA exerted an 94 
aggregation inhibitor effect, thereby providing individual particles [14]. L-leucine (LEU) was 95 
applied to enhance the dispersity of the particles and thereby improve the aerosolization and the 96 
flowability of the powders [15], [16]. Our works correlated with the positive effect of LEU on the 97 
aerodynamic properties, due to LEU decreases the deposition in the upper airways and increased 98 
the emitted fraction during inhalation [17], [18].  99 
 In the following work, we formulated micrometer-sized carrier-free DPI-s using spray-drying, 100 
containing previously nanonized active ingredient by wet milling. The novelty of the present work 101 
is the “nano-in-micro” structure of the DPI. We did the morphology, rheology, structure, 102 
dissolution, diffusion and aerodynamic characterization of the samples. We wanted to target the 103 
respiratory zone with the micrometric particles. Thanks to the particle size reduction of the poorly 104 
water-soluble MX and therefore the increase of the specific surface area, we could improve the local 105 
dissolution in the lung fluid and permeability to the epithelium. Our product could provide an 106 
effective treatment for serious local pulmonary diseases. 107 
2. Materials and Methods  108 
2.1. Materials 109 
Meloxicam (MX) (Egis Pharmaceuticals PLC., Budapest, Hungary) was used as an active 110 
ingredient. As additives poly-vinyl-alcohol 3-88 (PVA), (ISP Customer Service GmBH, Cologne, 111 
Germany) and L-leucine (LEU), (AppliChem GmbH, Darmstadt, Germany) were applied. 112 
2.2. Preparation method 113 
We used a two-step preparation protocol. First, the pre-nanosuspension was prepared by wet 114 
milling technology, using PVA and MX. The final microsized powders were obtained with co-spray 115 
drying of the diluted suspension and LEU (Fig. 1.). 116 
 117 
Figure 1. Two-step preparation method of the samples. 118 
2.2.1. Wet milling 119 
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We applied a combined wet milling technique, which was optimized by our research group’s 120 
previous work [13]. We dissolved 2.5 g of PVA in purified water and the volume of the final 121 
solution was 100 mL. 2.00 g of MX was suspended in 18.0 g of 2.5% (mass/volume) PVA solution. 122 
20.0 g of ZrO2 beads were the milling medium in a planetary ball mill (Retsch Planetary Ball Mill PM 123 
100 MA, Retsch GmbH, Haan, Germany). The milling parameters were the following: 60 min, 500 124 
rpm. As the result of the wet milling, we got a nanosized pre-suspension containing MX and PVA. 125 
The nanosuspension was diluted with purified water to 500 ml. The final concentration of the MX 126 
suspension was 4 g/L. 127 
2.2.2. Co-spray drying 128 
 We prepared different compositions by adding a various amount of LEU as shown in Table 1. 129 
A magnetic stirrer was used for sample homogenization (AREC.X heating magnetic stirrer, Velp 130 
Scientifica Srl, Italy). The inhalable microparticles were produced by spray-drying using a 131 
spray-dryer equipped with a two-fluid nozzle of 0.7 mm (Büchi Mini Spray Dryer B-191, Büchi, 132 
Flawil, Switzerland). Based on the preliminary experiments spray drying properties were the 133 
following: inlet temperature: 165 °C, outlet temperature: 100 °C, aspirator capacity: 85 %, airflow 134 
rate: 500 L/h, feed pump rate: 10 %. The yield was calculated as the ratio of the mass of the particles 135 
collected after spray-drying to the mass of the solid content of the initial nanosuspension. We 136 
managed to increase the yield of spray-drying with the addition of LEU. Low spray-drying yields 137 
are indicative of cohesive powders. LEU reduced the cohesion between the particle, therefore the 138 
improvement of the spray-drying yield [19]. 139 
Table 1. Composition of the samples and the yield of spray-drying. 140 
Samples MX (g/L) PVA (g/L) LEU (g/L) Yield* (%) 
nanoMX1_LEU0 4.00 0.90 0.00 45.41 ± 5.10 
nanoMX1_LEU0.5 4.00 0.90 2.00 57.56 ± 1.36 
nanoMX1_LEU1 4.00 0.90 4.00 58.43 ± 6.36 
*Data are means ± SD (n = 3 independent measurements). 
2.2.3. Physical mixtures 141 
 We prepared physical mixtures of the raw materials. The compositions were the same as for 142 
the spray-dried samples (Table 2.). During our measurements, we compared the properties of the 143 
spray-dried samples to the physical mixtures. 144 
Table 2. Composition of the physical mixtures. 145 
Samples MX (g) PVA (g) LEU (g) 
pmMX1_LEU0 4.00 0.90 0.00 
pmMX1_LEU0.5 4.00 0.90 2.00 
pmMX1_LEU1 4.00 0.90 4.00 
2.3. Determination of particle size and distribution 146 
 Laser diffraction was used to determine the particle size and the particle size distribution of 147 
our samples (Malvern Mastersizer Scirocco 2000, Malvern Instruments Ltd., Worcestershire, United 148 
Kingdom). The wet dispersion unit was used to measure the particle size of the nanosuspension. We 149 
set the refractive index of MX (1.720) and measured it in purified water with 2000 rpm stirring. The 150 
dry dispersion unit was used to observe the spray-dried microcomposites. Approximately 0.5-1.0 g 151 
of product was loaded into the feeding tray. The dispersion air pressure was adjusted to 3.0 bar and 152 
75 % vibration feed was used. Each sample was measured in triplicate. The particle size distribution 153 
was characterized by the D[0.1] (10% of the volume distribution is below this value), D[0.5] (the 154 
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volume median diameter is the diameter where 50% of the distribution is above and 50% is below) 155 
and D[0.9] (90% of the volume distribution is below this value) values. The size distribution Span 156 
was calculated according to (Eq. 1). A high Span value denotes a broad particle size distribution. 157 
The higher the Span value, the broader the particle size distribution [20]. We obtained the specific 158 
surface area (SSA) data, which predicts the dissolution and permeability properties of the samples. 159 




2.4. Investigation of morphology 160 
 Scanning electron microscopy (SEM), (Hitachi S4700, Hitachi Scientific Ltd., Tokyo, Japan) was 161 
used to characterize the morphology of the spray-dried formulation. We applied a high voltage of 162 
10 kV, an amperage of 10 mA and an air pressure of 1.3-13.1 mPa. A high vacuum evaporator and 163 
argon atmosphere were used to make the sputter-coated samples conductive with gold-palladium 164 
(Bio-Rad SC 502, VG Microtech, Uckfield, United Kingdom). The thickness of the gold-palladium 165 
coating was approximately 10 nm. For the particle size analysis of the active ingredient a public 166 
domain image analyzer software, ImageJ was used (https://imagej.nih.gov/ij/index.html). 167 
2.5. Density measurement 168 
The bulk and tapped densities of the formulations were measured by using an Engelsmann 169 
Stampfvolumeter (Ludwigshafen, Germany) [21]. A 10 cm3 cylinder was filled with 1.5-2.0 cm3 of 170 
powder to calculate bulk density. Then it was tapped 1000 times. The tapped density of the samples 171 
was calculated compared to the volume before and after the taps. We calculated the flow characters 172 
(Eq. 2, 3) of the samples from the bulk (ρb) and tapped (ρt) density. All samples were measured in 173 
triplicate. 174 




Carr index = 
(ρt-ρb)
ρt
*100  (3) 
2.6. Determination of the interparticle interactions 175 
Around 0.10 g of the samples were pressed on a 1 ton hydraulic press (Perkin Elmer hydraulic 176 
press, Specac Inc., Waltham, USA). Six pastilles were obtained from each sample. We did three 177 
parallel measurements with each composition. Three pastilles per sample were dripped with polar 178 
liquid (4.8 µl of purified water) and the other three pastilles were dripped with non-polar solvent 179 
(2.0 µl of diiodomethane). Contact angle was detected in an interval of 1 to 25 s with a Dataphysics 180 
OCA 20 apparatus (Dataphysics Instrument GmbH, Filderstadt, Germany) [22]. We obtained the contact 181 
angles of the two applied fluids. The surface free energy (γs) of the composites, which consists of 182 
the polar part (γsp) and the disperse part (γsd), so (γs= γsp+γsd), was calculated based on the 183 
Wu-equation. The surface tension of the used liquids is known in the literature: distilled water 184 
γp=50.2 mN/m, γd=22.6 mN/m and diiodomethane γp=1.8 mN/m, γd=49 mN/m. We can express the 185 
Wu equation (Eq. 4), where θ=contact angle, γ=surface free energy, s=solid phase, l=liquid phase, 186 







  (4) 
Polarity (Pol) was calculated as the ratio of the surface free energy of the polar component and 188 
surface free energy multiplied by 100. (Eq. 5). 189 





*100  (5) 
Cohesion work (Wc) was determined as twice the surface free energy (Eq. 6). 190 
Wc=2*γs (6) 191 
2.7. Structural analysis 192 
 To establish the crystalline character of the spray-dried samples X-ray powder diffraction 193 
(XRPD) spectra were recorded with a BRUKER D8 Advance X-ray diffractometer (Bruker AXS 194 
GmbH, Karlsruhe, Germany). The radiation source was Cu Kλ1 radiation (λ=1.5406 Å). Measurement 195 
conditions were the following: Cu target, Ni filter, 40 kV voltage, 40 mA current, time constant 196 
0.1°/min, angular step 0.010° over the interval 3-40°. We used the DIFFRACT plus EVA 28 software 197 
for the evaluation. 198 
2.8. Thermoanalitycal analysis 199 
 The differential scanning calorimetry measurements were made with a Mettler Toledo DSC 200 
821e thermal analysis system with the STARe thermal analysis program V9.1 (Mettler Inc., 201 
Schwerzenbach, Switzerland). Approximately 2-5 mg of the samples were examined in the 202 
temperature range between 25 °C and 300 °C. The heating rate was 5 °C/min. Argon was the carrier 203 
gas at a flow rate of 10 L/h during the investigation. 204 
2.9. In vitro dissolution test 205 
 No in vitro dissolution test for powders for inhalation exists in the current Pharmacopeia. We 206 
applied a modified paddle method (Hanson SR8 Plus, Teledyne Hanson Research, Chatsworth, Caz, 207 
USA) from the European Pharmacopeia [23] to examine the release of MX from the samples. The 208 
capacity of the vessel was 100 mL instead of 1000 mL and the size of the stirrer was smaller. We 209 
designed the parameters of our measurement based on the circumstances of the human airways 210 
[24]. The medium was a simulated lung medium, which contained NaCl, NaHCO3, CaCl2, 211 
NaH2PO4, H2SO4, and glycine [25]. The volume of the medium was 50 mL based on the estimated 212 
volume of the lung fluid [26]. The pH of the medium was 7.4 ± 0.1. The temperature was set at 37 213 
°C. The samples contained 1.5 mg of MX, which is one-tenth of the oral dose of the API. During 214 
pulmonary delivery we can reduce, the amount of API, compared to the oral dose. We chose this 215 
amount of API, based on a salbutamol dosage recommendation [27]. Applying these doses of our 216 
products were safe to use. Previous investigations proved that the API and the excipients had no 217 
cytotoxic effect in that concentration on the cells [28]. The paddle was rotated at 100 rpm and the 218 
sampling was performed up to 60 min. The total fraction of the samples was dispersed in the 219 
medium. We took 5 mL of the dissolution medium after 5, 10, 15, 30, and 60 min. The medium was 220 
replenished every time the sample was withdrawn. After filtration, (pore size: 0.45 µm, Millex-HV 221 
syringe-driven filter unit, Millipore Corporation, Bedford, USA) and dilution, the MX contents of the 222 
samples were determined by spectrophotometry at λ=362 nm (ATI-UNICAM UV/VIS 223 
Spectrophotometer, Cambridge, United Kingdom). Three parallel measurements took place with the 224 
formulations. 225 
2.10. In vitro diffusion test 226 
We would like to demonstrate the permeability from the lung fluid to the epithelial cells of the 227 
lung. A modified horizontal diffusion cell was used to investigate the in vitro permeability of the 228 
samples [26]. The donor phase (9 mL) was simulated lung medium (pH = 7.4). Phosphate buffer 229 
(pH = 7.4) was used as the acceptor phase (9 mL) modelling the circumstances of the epithelial cell. 230 
Between the two phases, there was a cellulose membrane (RC 55 WhatmanTM GE Healthcare Life 231 
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Sciences, Buckinghamshire, United Kingdom) impregnated with isopropyl myristate. The actual 232 
diffusion surface was 0.785 cm2. The rotation of the stirring bar was set to 300 rpm. The temperature 233 
was 37 °C. We measured 1.5 mg MX contents of the samples. First, the API released in the 234 
simulated lung fluid, then diffused through the membrane to the phosphate buffer. The amount of 235 
diffused MX was determined real-time at λ=362 nm until 60 minutes with sonda 236 
(FDP-7UV200-VAR, Avantes, Apeldoorn, The Netherlands) spectrophotometer 237 
(Avaspec-ULS2048-USB2, Avantes, Apeldoorn, The Netherlands) in the acceptor phase [29]. The 238 
samples were measured three times. 239 
 The flux (J) [µg/cm2/h] of the active ingredient was calculated from the quantity of MX which 240 
permeated through the membrane, divided by the surface of the membrane insert and the duration 241 




  (7) 
The permeability coefficient (Kp) [cm/h] was determined from the flux and the MX 243 




  (8) 
2.11. In vitro aerodynamic measurements 245 
 The aerosolization efficacy of the spray-dried formulations was assessed in vitro, using an 246 
Andersen Cascade Impactor (ACI), (Apparatus D, Copley Scientific Ltd., Nottingham United Kingdom) 247 
[30]. The inhalation flow rate was set to 28.3±1 L/min (High-capacity Pump Model HCP5, Critical Flow 248 
Controller Model TPK, Copley Scientific Ltd., Nottingham, UK). Table 3. Shows the cut-off aerodynamic 249 
diameter for stages of ACI at a flow rate of 28.3 L/min [31]. The actual flow rate through the 250 
impactor was measured by a mass flow meter (Flow Meter Model DFM 2000, Copley Scientific Ltd., 251 
Nottingham, UK). The inhalation time was 4 s for one inhalation. These parameters were lead to an 252 
inhalation volume of 1.89 L, which was similar to the inhalation volume of COPD patients [32]. 253 
Breezhaler® single dose devices (Novartis International AG, Basel, Switzerland) were used, with 254 
transparent, size 3 gelatine capsules (Capsugel, Bornem, Belgium) filled with 2.0–2.5 mg of powder, 255 
which contained 1-2 mg of MX. Four capsules were inhaled during one measurement. The inhaler 256 
was actuated twice for each capsule. Each sample was measured in triplicate. 257 
 To provide the pulmonary adhesive circumstances, the plates on the stages were coated with 258 
Span 85 and cyclohexane (1+99 w/w%) mixture. After inhalation, the device, the capsules, the 259 
induction port, the collection plates and the filter were washed with methanol and pH 7.4 260 
phosphate buffer (60+40 v/v%) to collect the deposited MX. The collected and dissolved MX was 261 
quantified by UV/Vis spectrophotometry (ATI-UNICAM UV/VIS Spectrophotometer, Cambridge, 262 
United Kingdom.) at a wavelength of λ=362 nm. 263 
The actual API content (%) of the spray-dried particles was measured by dissolving 1.0–1.1 mg 264 
of product in 25 mL of methanol:phosphate buffer (60:40 w/w%), which solution was used for the 265 
aerodynamic measurement too. The solutions were mixed for 10 min, 600 rpm and the API content 266 
was quantified by UV/Vis spectrophotometry (ATI-Unicam UV/VIS Spectrophotometer, Cambridge 267 
United Kingdom) at a wavelength of 362 nm.  268 
The aerodynamic properties were calculated from a plot of the cumulative percentage 269 
undersize of the API on log probability scale against the effective cut-off diameter using the 270 
KaleidaGraph program [31] [33]. The mass of drug particles with a size under 5 µm was defined as 271 
a fine particle dose (FPD). The amount of drug leaving the device and reaching the impactor was 272 
considered as the emitted dose (ED). The fine particle fraction (FPF) was calculated as the 273 
percentage ratio between FPD and ED. Emitted fraction (EF) was expressed as a percentage of the 274 
ED divided by the initial amount of API. The aerodynamic diameter is influenced by the inhalation 275 
flow rate, density, size and shape of the particle. The real size of the particle during inhalation is 276 
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expressed with the MMAD. The MMAD of the particles was determined from the same plot as the 277 
particle size corresponding to the 50% point of the cumulative distribution. For an inhalable and 278 
well-deposited powder, the MMAD should be in the 1–5 µm size range [34]. 279 
Table 3. Cut-off aerodynamic diameter for stages of ACI at a flow rate of 28.3 L/min. 280 











2.12. In silico characterization 282 
The in silico simulations were performed by the Stochastic Lung Deposition Model, which 283 
tracks the inhaled particles until their deposition or exhalation and computes the fraction of the 284 
particles deposited in each anatomical part of the respiratory system, that is, extrathoracic, 285 
bronchial and acinar regions [35]. The particle trajectories were simulated in an asymmetrical 286 
branching airway structure mimicking the realistic airways by selecting morphometrical 287 
parameters from the database of Raabe et al. [36]. The inputs of the computational model are 288 
different parameters characterizing the aerosol particles like density, shape or size, and the 289 
breathing parameters of the patient, such as inhaled volume, inhalation time, breath-hold time, 290 
exhalation time and breathing mode (nasal or oral). A more detailed description of the numerical 291 
model can be found in Koblinger and Hofmann [37]. In our work, aerodynamic particle size 292 
distributions of the samples measured by the Andersen Cascade Impactor technique served as the 293 
inputs for the numerical airway deposition model. The inhalation parameters corresponded to a 294 
COPD patient inhaling through Breezhaler®, whose inhaled volume and inhalation time values 295 
(IV=1.7 L, tin=3.2 s) matched the best the flow rate of the current impactor measurements. The 296 
computational deposition model was validated for the case of aerosol drugs in our earlier works 297 
[38] [39]. 298 
3. Results 299 
3.1. Particle size distribution 300 
We managed to prepare a nanosuspension using raw MX and 2.5% PVA dilution during the 301 
milling procedure. In the diluted suspension, the particle size of MX was 137.70 nm ± 4.965 nm, the 302 
SSA was 43.65 ± 5.318 m2/g. After spray-drying the size of the particles was applicable for 303 
pulmonary delivery since the D [0.5] values were in the 1-5 µm range and the distribution was 304 
monodisperse (Table 4.). The geometric diameter of spray-dried nanoMX1_LEU0 was around 3.2 305 
µm. Incorporating LEU in the formulations increased the geometric size of the spray-dried particles 306 
[40]. The distribution was monodisperse in all cases (Span < 2.0), which is essential for accurate 307 
dosing. The specific surface area (SSA) values increased compared to the raw materials, which 308 
predicted an improved dissolution profile.  309 
Table 4. Particle size of the initial API, the nanosuspension, the physical mixtures and the final 310 
samples. 311 
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Samples D [0.1]* (μm) D [0.5]* (μm) D [0.9]* (μm) Span* SSA* (m2/g) 
raw MX 2.719 ± 0.057 9.913 ± 0.371 29.49 ± 0.630 2.70 ± 0.043 1.09 ± 0.028 
MX suspension 0.067 ± 0.001 0.138 ± 0.005 0.555 ± 0.310 3.584 ± 2.056 43.65 ± 5.318 
pmMX1_LEU0 3.073 ± 0.030 13.10 ± 0.500 349.92 ± 34.86 26.47 ± 1.649 0.88 ± 0.025 
pmMX1_LEU0.5 5.426 ± 0.631 91.22 ± 17.90 357.57 ± 168.2 3.86 ± 1.101 0.40 ± 0.066 
pmMX1_LEU1 7.983 ± 0.092 110.67 ± 0.261 353.25 ± 47.24 3.12 ± 0.433 0.27 ± 0.002 
nanoMX1_LEU0 1.497 ± 0.046 3.186 ± 0.019 6.481 ± 0.193 1.56 ± 0.068 2.22 ± 0.031 
nanoMX1_LEU0.5 1.834 ± 0.007 3.800 ± 0.014 7.389 ± 0.030 1.46 ± 0.004 1.88 ± 0.024 
nanoMX1_LEU1 1.977 ± 0.093 4.396 ± 0.032 8.903 ± 0.186 1.58 ± 0.075 1.71 ± 0.051 
*Data are means ± SD (n = 3 independent measurements). 
3.2. Particle morphology 312 
The SEM pictures showed particles with a nearly spheroidal shape, which was the result of the 313 
optimized parameters of the co-spray-drying. The particles were produced from the droplets 314 
during the method, and the most stable shape for a droplet is the spherical form [41]. According to 315 
the SEM pictures, we observed that the presence of PVA prevented the aggregation. Particles were 316 
individually separated and displayed a regular size, which met the requirements for the 317 
formulation of a DPI [14]. Peclet number of LEU is greater than 1, which led to wrinkled particle 318 
morphology after spray-drying. This rough surface improved the dispersion of the particles, which 319 
reflecting low density and resulting in higher drug delivery into the low regions of the airways [18], 320 
[40], [42]. We could observe the nanosized active ingredient particles on the SEM pictures. We 321 
measured the diameter of the API with Image-J program. The size range of these was between 322 
120-140 nm (Table 4.). The diameter of the MX was correlated with the results of the 323 
nanosuspension. The images proved the “nano-in-micro” structure of the final powders. 324 
Table 5. Diameter of the API in the products determined by Image-J analyzes and the SEM images 325 
of the spray-dried samples. 326 










   






   
*Data are means ± SD (n = 100 independent measurements). 
3.3. Powder rheology 327 
The lower density of DPI particles could offer better flowability and improved deposition 328 
within the deeper airways. Thanks to the additives, density was reduced to under 0.3 g/cm3. The 329 
usual density of DPIs is about 1 g/cm3, so our samples can be considered as low-density 330 
formulation. The lower the tap density (0.04–0.25 g/cm3) is, the greater the respirable fraction [43]. 331 
The higher amount of LEU included in the sample nanoMX1_LEU1 was found to further reduce 332 
density as demonstrated by the more wrinkled appearance of the particles [17]. The Hausner ratio 333 
(HR) was between 1.4 and 1.8. The Carr index (CI) results were in the range of 27 and 43 (Table 6.). 334 
The result indicates poor flowability, but it is similar to other carrier-free formulations in the 335 
literature [44]. HR and CI values are also responsible for the aerosolization performance [45]. 336 









Carr index* Flowability 
nanoMX1_LEU0 0.177 ± 0.020 0.262 ± 0.001 1.488 ± 0.048 32.39 ± 7.232 Very poor 
nanoMX1_LEU0.5 0.156 ± 0.009 0.274 ± 0.004 1.759 ± 0.084 43.09 ± 2.704 
Very, very 
poor 
nanoMX1_LEU1 0.147 ± 0.013 0.204 ± 0.012 1.398 ± 0.209 27.65 ± 10.82 Very poor 
*Data are means ± SD (n = 3 independent measurements). 
3.4. Interparticular interactions 338 
Contact angle measurements were performed to calculate the polarity and the cohesive work 339 
(Wc) characteristic of the materials. The wettability study revealed that the microcomposites had a 340 
more hydrophilic character as compared with hydrophobic MX. With the use of PVA polarity 341 
increased, which predicted better dissolution results in simulated lung medium compared to raw 342 
MX. The highest polarity values were obtained with nanoMX1_LEU0. The lipophilic component 343 
LEU decreased the polarity of the samples. In the case of samples containing LEU, cohesivity 344 
decreased between the spherical, rough particles, so the presence of LEU caused the decrease in Wc 345 
(Table 7.). The lower cohesivity of particles could result in more effective deposition properties. 346 




γp [mN/m] γ [mN/m] Wc [mN/m] Pol [%] 
MX 45.49 ± 0.09 13.89 ± 0.13 59.83 ± 0.22 118.76 ± 0.44 23.39 ± 0.15 
PVA 45.65 ± 0.10 36.89 ± 0.20 82.54 ± 0.30 165.08 ± 0.60 44.69 ± 0.11 
LEU 30.00 ± 0.07 0.50 ± 0.17 30.50 ± 0.24 61.00 ± 0.48 1.639 ± 0.20 
pmMX1_LEU0 42.62 ± 0.12 30.65 ± 0.48 73.27 ± 0.60 146.54 ± 1.20 41.83 ± 0.56 
pmMX1_LEU0.5 36.57 ± 0.34 25.63 ± 0.27 62.20 ± 0.61 124.40 ± 1.22 41.21 ± 0.84 
pmMX1_LEU1 34.01 ± 0.55 16.57 ± 0.36 50.58 ± 0.91 101.16 ± 1.82 32.76 ± 0.44 
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nanoMX1_LEU0 42.34 ± 0.08 31.03 ± 0.62 73.38 ± 0.70 146.76 ± 1.40 42.29 ± 0.44 
nanoMX1_LEU0.5 36.15 ± 0.95 25.69 ± 0.45 61.84 ± 0.51 123.68 ± 1.02 41.54 ± 1.07 
nanoMX1_LEU1 33.39 ± 0.86 16.59 ± 0.11 49.98 ± 0.97 99.96 ± 1.94 33.19 ± 0.43 
*Data are means ± SD (n = 3 independent measurements). 
3.5. X-ray powder diffraction results 348 
X-ray powder diffraction was used to characterize the crystalline state of MX after the 349 
preparation process. The XRPD pattern of the raw materials demonstrated the crystalline structure 350 
of MX and LEU, as expected. Raw MX has characteristic peaks with the highest intensities at 6.6°, 351 
11.4°, 13.1°, 13.5°, 15.1°, 18.7°, 19.3°, 25.9° and 26.4° 2-theta peaks indicating its crystalline structure 352 
[46]. We detected the characteristic peaks of LEU at 6.12, 24.39, 30.61 2-theta peak [47]. In the case of 353 
the products, the intensities of the characteristic peaks decreased (Fig. 2.). The presence of PVA had 354 
no effect on the diffractograms. In the course of milling and spray-drying, a decrease in crystallinity 355 
was perceptible, which was determined via the mean of the decrease of the total area beneath the 356 
curve of the characteristic peaks compared to the physical mixtures. After treatment, ~71% of MX 357 
remained crystalline for the nanoMX1_LEU0, ~52% for the nanoMX1_LEU0.5 and ~53% for the 358 
nanoMX1_LEU1. The other part of the active ingredient became amorphous during the preparation 359 
process. The preliminary stability test showed no changes in the structure after one month. 360 
 361 
Figure 2. XRPD results of the raw materials (LEU, PVA, MX), the physical mixtures (pmMX1_LEU0, 362 
pmMX1_LEU0.5, pmMX1_LEU1) and the spray-dried samples (nanoMX1_LEU0, nanoMX1_LEU0.5, 363 
nanoMX1_LEU1). 364 
3.6. Thermoanalytical results 365 
DSC was employed to investigate the melting of PVA, LEU and MX in the raw form, in the 366 
physical mixtures and in the prepared products (Fig 3.). PVA had no endothermic peak. LEU had 367 
an endothermic peak at 294,41 °C. The DSC curves of raw MX showed a sharp endothermic peak at 368 
264.03 °C, reflecting its melting point and crystalline structure. After milling and spray drying, the 369 
DSC curves in all cases exhibited broader endothermic peaks of MX, indicating that the crystallinity 370 
of the drug decreased. The residual MX crystals in the products melted at a lower temperature than 371 
the crystals of raw MX due to the smaller particle size and the increased degree of amorphization. 372 
This was promoted by PVA, which was softened at 85 °C as glass transition temperature (Tg) value. 373 
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Figure 3. DSC results of the raw materials, (PVA, LEU, MX), the physical mixtures (pmMX1_LEU0, 375 
pmMX1_LEU0.5, pmMX1_LEU1) and the spray-dried samples (nanoMX1_LEU0, nanoMX1_LEU0.5, 376 
nanoMX1_LEU1).  377 
3.7. In vitro dissolution results 378 
The initial API showed poor water-solubility as we mentioned above. The formulations were 379 
compared to raw MX and the physical mixtures. The results of the dissolution study confirmed our 380 
predictions (Fig. 4.). The released amount of MX was the lowest in the case of samples containing 381 
raw material during the investigation. The spray-dried samples showed enhanced drug release 382 
compared to the reference samples. Approximately half of the drug was released from the samples 383 
containing nanonized API within the first 5 min and 65-85 % released within an hour. These 384 
improvements in dissolution profile could be related to nanosizing effects, higher specific surface 385 
area and amorphization. The presence of PVA inhibited the aggregation and increased polarity, 386 
which helped to release the MX in the simulated lung medium. Applying LEU reduced the 387 
cohesion between the particles, so larger a amount of MX was liberated from the powder than 388 
without LEU. The highest amount of API was released from the nanoMX1_LEU0.5, because the 389 
higher LEU concentration reduced the polarity of the products. The results of our formulations are 390 
promising in the local pulmonary therapy. The prolonged presence of the particles gives enough 391 
time to release the nanosized API. Therefore the clearance mechanism of the lung will reduce the 392 
delivered drug dose less [6]. 393 
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 394 
Figure 4. In vitro dissolution results of the API (rawMX), the physical mixtures (pmMX1_LEU0, 395 
pmMX1_LEU0.5, pmMX1_LEU1) and the prepared samples (nanoMX1_LEU0, nanoMX1_LEU0.5, 396 
nanoMX1_LEU1). Data are means ± SD (n = 3 independent measurements). 397 
3.8. In vitro permeability results 398 
We investigated the diffused amount of API from the simulated lung medium through a 399 
membrane to the epithelium. The high surface area achieved by the nanosized particles was the 400 
main factor affecting the rate of passive diffusion. Diffusion from the samples was faster and 401 
reached higher values than from raw MX and the physical mixtures (Fig. 5.). The diffused MX 402 
concentrations (60-90 µg/cm2 ) were promising if we interpolate them to the total surface of the 403 
lung. We reached the highest values with the nanoMX1_LEU0.5 formulation, which was correlated 404 
with the result of the in vitro dissolution test. The products showed a significantly increased flux (J) 405 
and permeability coefficient (Kp) compared to the raw materials (Table 8.). The higher diffusion is 406 
connected to the higher surface area produced by the nanoparticles. A large amount of API could 407 
get into the epithelium with our spray-dried formulations, as a result of that, they could be effective 408 
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 410 
Figure 5. In vitro diffusion results of the API (rawMX), the physical mixtures (pmMX1_LEU0, pmMX1_LEU0.5, 411 
pmMX1_LEU1) and the prepared samples (nanoMX1_LEU0, nanoMX1_LEU0.5, nanoMX1_LEU1). SD < ± 2% 412 
(n = 3 independent measurements). 413 
Table 8. In vitro permeability results of the samples. 414 
Samples J (μg/cm2/h) Kp (cm/h) 
rawMX 28.23  0.1394 
pmMX1_LEU0 34.69 0.2081 
pmMX1_LEU0.5 37.45 0.2247 
pmMX1_LEU1 33.25 0.1995 
nanoMX1_LEU0 61.80 0.3708 
nanoMX1_LEU0.5 86.90 0.5214 
nanoMX1_LEU1 73.58 0.4415 
SD < ± 2% (n = 3 independent measurements). 
 415 
3.9. In vitro aerodynamic results 416 
The in vitro aerodynamic results were demonstrated in Table 9. The MMAD values were 417 
between 1.55-2.33 µm, wherewith we could target the deeper airways [48]. The samples had FPF 418 
values between 72-76%, which is higher than the FPF values of the Breezhaler formulations on the 419 
market [32]. We can see the distribution of the products on the stages of the Andersen Cascade 420 
Impactor (Fig. 6.). The nanoMX1_LEU0 sample had 15% deposition in the upper airways, 25 % and 421 
27 % deposited on the 3rd and 4th stages. The FPF value here was the most outstanding (75.67 %). 422 
The application of LEU improved the aerosolization of the products due to the reduced cohesion 423 
between the particles, they de-aggregated during inhalation. The samples had smaller MMAD 424 
(nanoMX1_LEU0.5: 1.74 µm, nanoMX1_LEU1: 1.55 µm) and flown deeper in the ACI, deposited on 425 
the filter. We got high FPF values (nanoMX1_LEU0.5: 72.81%, nanoMX1_LEU0.5: 73.63%). The 426 
emitted fraction (EF) in most of the samples were also high (around 72-84%), indicating a weak 427 
adhesive character between the powder and the capsule, so a large amount of the product could 428 


































Figure 6. In vitro distribution of the samples (nanoMX1_LEU0, nanoMX1_LEU0.5, nanoMX1_LEU1). Data are 432 
means ± SD (n = 3 independent measurements). 433 
















nanoMX1_LEU0 2.33 ± 0.08 
4.52 ± 
0.33 





8.26 ± 0.14 
93.81 ± 
2.99 
nanoMX1_LEU0.5 1.74 ± 0.35 
3.09 ± 
0.31 





5.07 ± 0.33 
55.48 ± 
0.78 
nanoMX1_LEU1 1.55 ± 0.06 
2.51 ± 
0.04 





4.53 ± 0.23 
51.46 ± 
0.66 
*Data are means ± SD (n = 3 independent measurements). 
 435 
3.10. In silico aerodynamic results 436 
Figure 7. shows the deposition fractions of the samples within the extrathoracic airways and 437 
within different regions of the lung: the bronchial and acinar pulmonary regions. The results were 438 
calculated with breath-holding time after inhalation: 5 s and 10 s. Using breath-holding time of 10 s, 439 
the deposited fraction improved in all cases. The extrathoracic deposition is lower for the LEU 440 
containing products, thanks to improved dispersity. The lower deposition in the lung was because 441 
this method was defined the deposited amount on the filter, as an exhaled fraction. The 442 
nanoMX1_LEU0 reached the highest deposition (47.47%) in the lung (Table 10.). In all cases, higher 443 
values were obtained in the acinar region than in the bronchial region, which proved the delivery 444 
into the lower parts of the lung. It is a more proper approach to the real distribution in the airways 445 
than the in vitro method. However, these data are also promising for us because in various lung 446 
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 448 
Figure 7. In silico aerodynamic results of the products (nanoMX1_LEU0, (nanoMX1_LEU0_5s, 449 
nanoMX1_LEU0_10s, nanoMX1_LEU0.5_5s, nanoMX1_LEU0.5_10s, nanoMX1_LEU1_5s, 450 
nanoMX1_LEU01_10s). Data are means ± SD (n = 3 independent measurements). 451 
Table 10. In silico aerodynamic properties with a breath-holding time of 10 s. 452 
Samples 
Deposited Fraction* (%) 
Extrathoracic  Lung Bronchial Acinar 
nanoMX1_LEU0 21.41 ± 2.79 46.73 ± 2.21 17.92 ± 2.93 28.81 ± 2.22 
nanoMX1_LEU0.5 14.45 ± 0.95 27.55 ± 0.99 10.72 ± 1.30 16.83 ± 1.34 
nanoMX1_LEU1 10.07 ± 0.47 22.44 ± 0.31 8.64 ± 0.54 13.80 ± 0.35 
*Data are means ± SD (n = 3 independent measurements). 
5. Discussion 453 
The purpose of our research work was to develop a carrier-free „nano-in-micro” DPI system 454 
including the advantages of nanonized active ingredient. We successfully worked out a 455 
“nano-in-micro” structured particle preparation method. We nanonized the API by wet milling and 456 
prepared micrometric sized particles by spray-drying. The samples containing MX, stabilizing 457 
additive (PVA), and aerosolization adjuvant (LEU) were characterized. From the nanosuspension, 458 
which contained MX nanoparticles (d=137 nm) we managed to prepare nearly spherical 459 
microparticles with a size of 3-4 µm. By adding LEU, we could improve the yield (58 %) of the 460 
spray-drying method. The specific surface area of the powders (1.7-2.2 m2/g) increased compared to 461 
the raw materials. With the low density (0.20-0.27 g/cm3) formulations, we achieved proper 462 
aerosolization properties. With the application of PVA, the polarity of the samples increased and 463 
thanks to LEU, the cohesivity of the particles became lower. Part of the active ingredient was 464 
detected in an amorphous state according to the XRPD and DSC measurements. Due to the particle 465 
size reduction, improved surface area, amorphization and additives, dissolution was higher in the 466 
lung medium, compared to the poorly water-soluble raw material, and the in vitro permeability of 467 
the samples also improved (61-87 µg/cm2/h). The dissolution and permeability results were 468 
beneficial to local delivery. Samples showed good aerosolization properties during the in vitro 469 
aerodynamic measurements: FPF above 72 %, MMAD between 1.55-2.33 µm and ED above 72 %. 470 
The application of LEU increased the deposition in the deeper airways. The Andersen Cascade 471 
Impactor has limitations, the data are usually higher than they could be in real circumstances [49]. 472 
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airways. They showed higher deposition in the acinar region than in the bronchial region. This 474 
method also just an approximated translation to patients. 475 
6. Conclusion 476 
The presented DPI offers an effective local treatment for lung diseases to prove it, it should be 477 
tested in vivo soon. The execution of the stability measurement is also important because of the 478 
“nano-in-micro” structure and the partial amorphization of the active ingredient. 479 
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